Argenx Discontinued Phase 3 Sjögren's Study
The pharmaceutical company halted its late-stage trial for efgartigimod after the drug failed to meet primary endpoints.
Updated on Oct. 8, 2026 in Arthritis
Live Poll
Do you trust pharmaceutical companies to prioritize patient health outcomes over successful clinical trial results?
Argenx has officially discontinued the Phase 3 UNITY study evaluating the efficacy of efgartigimod SC for adults with moderate-to-severe Sjögren's disease. The decision follows a recommendation from an independent oversight body that concluded the trial would not meet its primary objective.
Why it matters
The failure of the UNITY study represents a significant setback in the search for new treatments for Sjögren's disease, an autoimmune condition characterized by inflammation. Research continues to be vital given the scarcity of approved therapeutic options for patients living with the chronic disorder.
The Phase 3 trial utilized a 1:1 patient randomization ratio between the efgartigimod SC and placebo groups. Sjögren's disease itself is marked by a 9:1 female-to-male incidence ratio, though these specific study results failed to meet primary endpoints.
The players
Argenx
An immunology-focused biotechnology company based in Amsterdam, the Netherlands, that specializes in developing antibody-based medicines for autoimmune diseases.
Independent Data Monitoring Committee
An objective panel of experts tasked with reviewing unblinded interim clinical trial data to ensure participant safety and study integrity.
The details
An interim analysis conducted by an Independent Data Monitoring Committee determined that the study reached the threshold for futility, prompting the discontinuation. Although the drug failed to show the required clinical benefit, the company reported that safety results remained consistent with the established profile of efgartigimod and no new safety signals were identified.
Timeline
October 8, 2026: Argenx announced the discontinuation of the UNITY study.
The Big Picture
The discontinuation of the UNITY clinical study of efgartigimod marks a departure from the recent successes in the company's antibody therapy pipeline. This setback highlights the significant challenges inherent in developing biologics for complex autoimmune conditions like Sjögren's.
Patients currently enrolled in the UNITY study will see the trial process conclude immediately following the company's data review. Those seeking treatment for Sjögren's should consult with their healthcare providers regarding existing standard-of-care options and other available clinical research.
The takeaway
The termination of this trial reinforces the high rate of attrition in late-stage autoimmune drug development. Argenx plans to complete a full data analysis and share findings with the patient community to help inform future research directions.
Further reading
For broader context on current clinical advancements, visit the Arthritis section.
Live Poll
Do you trust pharmaceutical companies to prioritize patient health outcomes over successful clinical trial results?
